MANF - if we can get one Orphan indication partnership (via a Pharmaceutical firm); it will open a floodgate of other opportunities for this molecule. I am surprised their hasn't been much communicated regarding the Parkinsons disease area.
If I remember correctly, we are promised more Orphan drug data in other indications...as it was promised within weeks (see below):
Via the Chairmans blog released on August 14th (this occurred after the Orhpan data for Retinitis Pigmentosa):
"As we continue our pursuit of identifying a variety of orphan indications for MANF, this first success is a major milestone. When data becomes available in the coming weeks on different applications, we will begin to spend some time reprioritizing our MANF pipeline to ensure that we are maximizing shareholder value, while simultaneously ensuring that we are expeditiously moving MANF forward in the various indications where MANF has shown benefit pre-clinically. We intend to rely heavily on not-for-profit funding for certain indications in order to minimize shareholder dilution while maximizing patient benefit as we move MANF forward. The economies of scale created by having a single therapeutic candidate treat multiple diseases cannot be overstated, as development milestones in one area support further development in the others. The Company’s orphan drug strategy outlined in November of 2012 is beginning to bear fruit and we intend to pursue orphan diseases aggressively as we see this as the most effective and expeditious route to getting MANF to patients".
